Security
Emmaus Life Sciences, Inc Common Stock · EMMA
EMMAOTCCommon stockCurrentCIK 822370Updated Nov 16, 2026
EMMA price & chart
Loading TradingView…
OTC:EMMA on TradingView ↗About the company
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus’ application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.
In the news
Emmaus Life Sciences Reports Quarterly Financial Results News provided by Emmaus Life Sciences, Inc. Aug 14, 2025, 15:13 ET Share this article Share to X Share this article Share to X TORRANCE, Calif. , Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA ), a commercial-stage bioph ↗
Recent filings
NT 10-Q filing
4 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-K filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 20,756,000Source | 27,343,000Source | 16,370,000Source | 23,344,000Source | 25,939,000Source | 18,696,000Source | 22,478,000Source | 29,543,000Source | 21,436,000Source | 23,602,000Source | 35,179,000Source | 48,225,000Source |
| Property, Plant and Equipment, NetUSD | 128,000Source | 49,000Source | 86,000Source | 143,000Source | 54,000Source | 98,000Source | 41,000Source | 57,000Source | 113,000Source | 46,000Source | 59,000Source | 75,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 293,000Source | 1,255,000Source | 2,808,000Source | 886,000Source | 1,525,000Source | 1,072,000Source | 1,333,000Source | 1,712,000Source | 2,127,000Source | 1,389,000Source | 2,547,000Source | 2,021,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,619,000Source | 4,938,000Source | 709,000Source | 2,071,000Source | 4,598,000Source | 2,048,000Source | 2,061,000Source | 2,990,000Source | 2,804,000Source | 2,623,000Source | 5,524,000Source | 375,000Source |
| Inventory, NetUSD | 1,213,000Source | 1,610,000Source | 1,589,000Source | 1,313,000Source | 1,628,000Source | 1,909,000Source | 1,437,000Source | 1,527,000Source | 1,555,000Source | 1,635,000Source | 1,711,000Source | 2,379,000Source |
| Assets, CurrentUSD | 4,786,000Source | 9,204,000Source | 6,003,000Source | 5,015,000Source | 9,012,000Source | 5,995,000Source | 5,653,000Source | 7,844,000Source | 7,746,000Source | 6,767,000Source | 11,509,000Source | 6,289,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 661,000Source | 1,347,000Source | 897,000Source | 745,000Source | 1,261,000Source | 966,000Source | 822,000Source | 1,615,000Source | 1,260,000Source | 1,120,000Source | 1,727,000Source | 1,514,000Source |
| Operating Lease, Right-of-Use AssetUSD | 799,000Source | 1,719,000Source | 808,000Source | 830,000Source | 1,903,000Source | 736,000Source | 1,331,000Source | 2,082,000Source | 766,000Source | 1,530,000Source | 2,337,000Source | 2,799,000Source |
| Other Assets, NoncurrentUSD | 167,000Source | 312,000Source | 202,000Source | 168,000Source | 308,000Source | 203,000Source | 222,000Source | 310,000Source | 207,000Source | 222,000Source | 296,000Source | 263,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 80,244,000Source | 81,124,000Source | 82,546,000Source | 79,045,000Source | 82,953,000Source | 86,556,000Source | 81,079,000Source | 83,187,000Source | 85,044,000Source | 80,081,000Source | 82,935,000Source | 82,316,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 64,000Source | 64,000Source | 70,000Source | 64,000Source | 64,000Source | 70,000Source | 64,000Source | 62,000Source | 70,000Source | 64,000Source | 62,000Source | 50,000Source |
| Retained Earnings (Accumulated Deficit)USD | -268,116,000Source | -260,827,000Source | -272,063,000Source | -266,040,000Source | -262,654,000Source | -273,402,000Source | -264,905,000Source | -260,470,000Source | -270,067,000Source | -262,575,000Source | -256,122,000Source | -252,337,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -481,000Source | -2,016,000Source | -3,302,000Source | 1,239,000Source | -3,394,000Source | -3,647,000Source | -2,797,000Source | -1,870,000Source | -2,729,000Source | -2,995,000Source | -160,000Source | -2,619,000Source |
| Stockholders' Equity Attributable to ParentUSD | -59,488,000Source | -53,781,000Source | -66,176,000Source | -55,701,000Source | -57,014,000Source | -67,860,000Source | -58,601,000Source | -53,644,000Source | -63,608,000Source | -56,479,000Source | -47,756,000Source | -34,091,000Source |
| Additional Paid in Capital, Common StockUSD | 225,914,000Source | 225,867,000Source | 225,988,000Source | 225,905,000Source | 225,839,000Source | 225,988,000Source | 225,906,000Source | 225,503,000Source | 225,987,000Source | 225,896,000Source | 225,333,000Source | 220,815,000Source |
| Liabilities and EquityUSD | 20,756,000Source | 27,343,000Source | 16,370,000Source | 23,344,000Source | 25,939,000Source | 18,696,000Source | 22,478,000Source | 29,543,000Source | 21,436,000Source | 23,602,000Source | 35,179,000Source | 48,225,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 64,169,000Source | 64,131,000Source | 66,116,000Source | 62,076,000Source | 64,025,000Source | 70,537,000Source | 64,915,000Source | 62,428,000Source | 69,072,000Source | 63,555,000Source | 61,507,000Source | 54,323,000Source |
| Operating Lease, Liability, CurrentUSD | 348,000Source | 2,329,000Source | 390,000Source | 348,000Source | 903,000Source | 349,000Source | 2,676,000Source | 869,000Source | 348,000Source | 2,423,000Source | 865,000Source | 703,000Source |
| Accounts Payable, CurrentUSD | 5,362,000Source | 6,489,000Source | 4,348,000Source | 4,562,000Source | 7,214,000Source | 5,810,000Source | 4,807,000Source | 6,565,000Source | 5,979,000Source | 5,175,000Source | 5,887,000Source | 3,785,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,498,000Source | 1,076,000Source | 1,299,000Source | 1,584,000Source | 1,322,000Source | 1,324,000Source | 544,000Source | 1,561,000Source | 1,409,000Source | 815,000Source | 1,839,000Source | 2,553,000Source |
| Other Liabilities, NoncurrentUSD | 12,313,000Source | 13,676,000Source | 12,884,000Source | 13,128,000Source | 15,370,000Source | 12,418,000Source | 13,369,000Source | 16,967,000Source | 12,292,000Source | 13,465,000Source | 17,363,000Source | 21,714,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 9,562,000Source | 7,864,000Source | 9,944,000Source | 9,032,000Source | 8,163,000Source | 10,238,000Source | 8,740,000Source | 8,519,000Source | 9,321,000Source | 7,732,000Source | 8,174,000Source | 7,239,000Source |
| Long-term DebtUSD | 29,069,000Source | 29,298,000Source | 24,986,000Source | 29,732,000Source | 29,371,000Source | 26,558,000Source | 29,006,000Source | 29,436,000Source | 27,128,000Source | 28,965,000Source | 30,563,000Source | 30,418,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -3,335,000Source | -2,330,000Source | -7,492,000Source | -6,453,000Source | -3,733,000Source | -10,625,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 15,000Source | 5,000Source | 39,000Source | 22,000Source | 32,000Source | 53,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,000Source | 10,000Source | 25,000Source | 256,000Source | 1,262,000Source | 16,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -756,000Source | -562,000Source | 182,000Source | -2,900,000Source | 5,149,000Source | -607,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 351,000Source | -199,000Source | 21,000Source | -7,000Source | -650,000Source | -434,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -344,000Source | 279,000Source | -11,000Source | -2,286,000Source | -1,503,000Source | -5,073,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 2,171,000Source | 2,500,000Source | -432,000Source | -2,387,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 1,000Source | 12,000Source | 17,000Source | 26,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -702,000Source | -345,000Source | -1,425,000Source | -1,353,000Source | 2,477,000Source | 7,233,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,055,000Source | -56,000Source | 738,000Source | -1,158,000Source | 526,000Source | -258,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 808,000Source | 415,000Source | 2,528,000Source | 2,246,000Source | 2,453,000Source | 1,335,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -1,000Source | 0Source | 23,000Source | 48,000Source | 83,000Source | — |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | 15,000Source | 5,000Source | 14,000Source | 4,000Source | 15,000Source | 5,000Source | 39,000Source | 22,000Source | 32,000Source | 39,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -32,000Source | -117,000Source | 9,000Source | 134,000Source | -130,000Source | -152,000Source | 26,000Source | -148,000Source | -1,767,000Source | -2,662,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | 22,000Source | -141,000Source | 38,000Source | 245,000Source | -1,911,000Source | -2,773,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | -1,000Source | -2,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | — | -31,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -296,000Source | 0Source | 0Source | -212,000Source | -76,000Source | -164,000Source | -1,363,000Source | — | -821,000Source | -501,000Source |
| General and Administrative ExpenseUSD | — | — | 1,731,000Source | 2,799,000Source | 1,574,000Source | 2,307,000Source | 1,850,000Source | 2,339,000Source | 8,179,000Source | 10,687,000Source | 14,891,000Source | 13,170,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source | — | — | — | — | — | — | -1,713,000Source | -1,913,000Source |
| Income Tax Expense (Benefit)USD | — | — | 579,000Source | -1,000Source | -1,000Source | -590,000Source | 4,000Source | 4,000Source | 9,000Source | 29,000Source | -59,000Source | 60,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,076,000Source | 1,827,000Source | 1,339,000Source | -1,135,000Source | -3,335,000Source | -2,330,000Source | -7,492,000Source | -6,453,000Source | -3,733,000Source | -10,625,000Source |
| Operating ExpensesUSD | — | — | 2,436,000Source | 4,263,000Source | 2,183,000Source | 3,037,000Source | 2,637,000Source | 3,161,000Source | 11,365,000Source | 17,346,000Source | 24,715,000Source | 22,388,000Source |
| Operating Lease, ExpenseUSD | — | — | 90,000Source | 263,000Source | 103,000Source | 97,000Source | 90,000Source | 249,000Source | 500,000Source | 1,100,000Source | 1,200,000Source | 1,100,000Source |
| Debt Securities, Realized Gain (Loss) | — | — | — | — | — | — | — | — | — | — | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,378,000Source | 5,478,000Source | 6,318,000Source | 2,817,000Source | 1,982,000Source | 2,406,000Source | 12,453,000Source | 16,653,000Source | 29,597,000Source | 18,390,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | 695,000Source | 821,000Source | 3,791,000Source | -370,000Source | -823,000Source | -980,000Source | 231,000Source | -1,894,000Source | 3,540,000Source | -6,586,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,497,000Source | 1,826,000Source | 1,338,000Source | -1,725,000Source | -3,331,000Source | -2,326,000Source | -7,483,000Source | -6,424,000Source | -3,792,000Source | -10,565,000Source |
| Income Tax Expense (Benefit)USD | — | — | 579,000Source | -1,000Source | -1,000Source | -590,000Source | 4,000Source | 4,000Source | 9,000Source | 29,000Source | -59,000Source | 60,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,076,000Source | 1,827,000Source | 1,339,000Source | -1,135,000Source | -3,335,000Source | -2,330,000Source | -7,492,000Source | -6,453,000Source | -3,733,000Source | -10,625,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.03Source | 0.03Source | 0.02Source | -0.02Source | -0.05Source | -0.04Source | -0.12Source | -0.1Source | -0.07Source | -0.21Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.03Source | 0.03Source | 0.02Source | -0.02Source | -0.05Source | -0.04Source | -0.12Source | -0.1Source | -0.07Source | -0.21Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 63,865,571Source | 63,865,571Source | 70,188,263Source | 63,865,571Source | 70,188,263Source | 63,865,571Source | 64,038,795Source | 63,234,789Source | 53,105,388Source | 49,439,867Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 63,865,571Source | 63,865,571Source | 120,537,248Source | 63,865,571Source | 70,188,263Source | 63,865,571Source | 64,038,795Source | 63,234,789Source | 53,105,388Source | 49,439,867Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 9,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -32,000Source | -117,000Source | 9,000Source | 134,000Source | -130,000Source | -152,000Source | 26,000Source | -148,000Source | -1,767,000Source | -2,662,000Source |
| General and Administrative ExpenseUSD | — | — | 1,731,000Source | 2,799,000Source | 1,574,000Source | 2,307,000Source | 1,850,000Source | 2,339,000Source | 8,179,000Source | 10,687,000Source | 14,891,000Source | 13,170,000Source |
| Gross ProfitUSD | — | — | 3,131,000Source | 5,084,000Source | 5,974,000Source | 2,667,000Source | 1,814,000Source | 2,181,000Source | 11,596,000Source | 15,452,000Source | 28,255,000Source | 15,802,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -7,473,000Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | 0Source | — | — | — | — | — | — | -1,713,000Source | -1,913,000Source |
| Interest and Other IncomeUSD | — | — | 65,000Source | 145,000Source | 49,000Source | 67,000Source | 61,000Source | 73,000Source | 270,000Source | 274,000Source | 681,000Source | 680,000Source |
| Interest ExpenseUSD | — | — | 1,931,000Source | 1,338,000Source | 1,596,000Source | 1,678,000Source | 2,126,000Source | 1,256,000Source | 7,134,000Source | 5,492,000Source | 7,383,000Source | 5,013,000Source |
| Operating ExpensesUSD | — | — | 2,436,000Source | 4,263,000Source | 2,183,000Source | 3,037,000Source | 2,637,000Source | 3,161,000Source | 11,365,000Source | 17,346,000Source | 24,715,000Source | 22,388,000Source |
| Operating Lease, ExpenseUSD | — | — | 90,000Source | 263,000Source | 103,000Source | 97,000Source | 90,000Source | 249,000Source | 500,000Source | 1,100,000Source | 1,200,000Source | 1,100,000Source |
| Research and Development ExpenseUSD | — | — | 50,000Source | 146,000Source | 116,000Source | 56,000Source | 40,000Source | 176,000Source | 313,000Source | 657,000Source | 1,189,000Source | 1,725,000Source |
| Selling and Marketing ExpenseUSD | — | — | 655,000Source | 1,318,000Source | 493,000Source | 674,000Source | 747,000Source | 646,000Source | 2,873,000Source | 6,002,000Source | 8,635,000Source | 7,493,000Source |
| Debt Securities, Realized Gain (Loss) | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
ea030209901ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ea030209901ex99-1.htm PRESS RELEASE DATED AUGUST 14, 2026 Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, August 14, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2026. Highlights “Under our previously announced License and E…
Read attachment ↗ea029089601ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ea029089601ex99-1.htm PRESS RELEASE DATED MAY 15, 2026 Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, May 15, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2026. Highlights “We realized an 18% decline in net revenues for three mont…
Read attachment ↗ea028389901ex99-1.htm · 8-K · 2026-03-31
EX-99.1 2 ea028389901ex99-1.htm PRESS RELEASE DATED MARCH 30, 2026 Exhibit 99.1 Emmaus Life Sciences Reports Annual Financial Results Torrance CA, March 30, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2025. Highlights “We experienced a 25% decline in net revenues in 2025 as compa…
Read attachment ↗ea027134801ex99-1_emmaus.htm · 8-K · 2025-12-31
EX-99.1 2 ea027134801ex99-1_emmaus.htm PRESS RELEASE ISSUED DECEMBER 30, 2025 Exhibit 99.1 Emmaus Life Sciences Announces Strategic Transaction Enters into North American License and Exclusive Distribution Agreement Torrance CA, December 30, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTec…
Read attachment ↗ea027028901ex4-1_emmaus.htm · 8-K · 2025-12-22
EX-4.1 2 ea027028901ex4-1_emmaus.htm CONVERTIBLE PROMISSORY NOTE ISSUED DECEMBER 17. 2025 Exhibit 4.1 NEITHER THIS CONVERTIBLE PROMISSORY NOTE NOR THE SECURITIES ISSUABLE HEREUNDER HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION …
Read attachment ↗ea026551601ex99-1_emmaus.htm · 8-K · 2025-11-14
EX-99.1 2 ea026551601ex99-1_emmaus.htm NOVEMBER 14, 2025 PRESS RELEASE Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, November 14, 2025 - Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2025. Highlights “We experienced a 38% decline in n…
Read attachment ↗